LymphomaArchives
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma
Lymphoma 3 min.
Patients with classical Hodgkin’s lymphoma (HL) are usually treated with front-line combination chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). However, approximately 10–30% of patients suffer from relapsed or refractory disease [1], and the current standard...
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma
Lymphoma 5 min.
Central nervous system lymphoma (CNSL) is a highly aggressive subset of non-Hodgkin lymphoma with a dismal prognosis, including primary CNSL (PCNSL) and secondary CNSL (SCNSL) [1]. PCNSL is a distinct form of lymphoma confined to the brain, spinal cord, leptomeninges, or eyes, with no evidence of systemic...
Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients
Lymphoma 4 min.
Thromboembolism is a serious complication in patients with cancer, occurring 4 to 7 times more frequently than in the general population, with a mortality risk that is 6 to 8 times higher [1, 2–3]. Lymphoma patients are especially susceptible, with recent studies indicating that the incidence of...
Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study
Lymphoma 5 min.
Large B-cell lymphoma (LBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for up to 40% of all NHLs, and immunochemotherapy regimens with an anti-CD20 monoclonal antibody such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or dose-adjusted R-EPOCH (rituximab,...
Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany
Lymphoma 7 min.
Hematological malignancies include a heterogeneous group of lymphomas, multiple myelomas, and leukemias [1]. They differ according to cell type, clinical and molecular characteristics, prognosis, and treatment options [2, 3]. Follicular (FL) and diffuse large B-cell lymphomas (DLBCLs) are the most common...
